[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200101103T2 - CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar - Google Patents

CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar

Info

Publication number
TR200101103T2
TR200101103T2 TR2001/01103T TR200101103T TR200101103T2 TR 200101103 T2 TR200101103 T2 TR 200101103T2 TR 2001/01103 T TR2001/01103 T TR 2001/01103T TR 200101103 T TR200101103 T TR 200101103T TR 200101103 T2 TR200101103 T2 TR 200101103T2
Authority
TR
Turkey
Prior art keywords
inhibitor
controlled release
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
TR2001/01103T
Other languages
English (en)
Inventor
King Elizabeth
James Macrae Ross
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200101103(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of TR200101103T2 publication Critical patent/TR200101103T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus bir cGMP PDE-5 inhibitörü ihtiva eden, oral uygulamaya yönelik kontrollu bir sekilde saliverilen/serbest birakilan formülasyonlari ortaya koymaktadir. Formülasyonlar, diger hususlar meyaninda, cinsel yetersizligin tedavisinde veya önlenmesinde de faydalidir.
TR2001/01103T 1998-10-23 1999-10-04 CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar TR200101103T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
TR200101103T2 true TR200101103T2 (tr) 2001-09-21

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01103T TR200101103T2 (tr) 1998-10-23 1999-10-04 CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar

Country Status (44)

Country Link
US (1) US6964780B1 (tr)
EP (1) EP1123088B1 (tr)
JP (1) JP2002528408A (tr)
KR (1) KR20010075659A (tr)
CN (1) CN1324233A (tr)
AP (1) AP2001002125A0 (tr)
AT (1) ATE340562T1 (tr)
AU (1) AU756509B2 (tr)
BG (1) BG65323B1 (tr)
BR (1) BR9914718A (tr)
CA (1) CA2348086C (tr)
CO (1) CO5160262A1 (tr)
CR (1) CR6326A (tr)
CY (1) CY1106239T1 (tr)
CZ (1) CZ20011427A3 (tr)
DE (1) DE69933383T2 (tr)
DK (1) DK1123088T3 (tr)
DZ (1) DZ2923A1 (tr)
EA (1) EA004068B1 (tr)
EE (1) EE200100235A (tr)
ES (1) ES2272082T3 (tr)
GT (1) GT199900184A (tr)
HK (1) HK1041818A1 (tr)
HR (1) HRP20010285A2 (tr)
HU (1) HUP0104318A3 (tr)
ID (1) ID28232A (tr)
IL (1) IL141764A (tr)
IS (1) IS5865A (tr)
MA (1) MA26700A1 (tr)
MX (1) MXPA01004011A (tr)
MY (1) MY130727A (tr)
NO (1) NO20011933L (tr)
NZ (1) NZ510275A (tr)
OA (1) OA11664A (tr)
PA (1) PA8484301A1 (tr)
PE (1) PE20001286A1 (tr)
PL (1) PL195789B1 (tr)
PT (1) PT1123088E (tr)
SK (1) SK286473B6 (tr)
TR (1) TR200101103T2 (tr)
TW (1) TW577756B (tr)
UA (1) UA67802C2 (tr)
UY (1) UY25765A1 (tr)
WO (1) WO2000024383A1 (tr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7501409B2 (en) 2000-09-06 2009-03-10 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2566699C (en) * 2004-05-11 2016-02-16 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1896076A2 (en) * 2005-06-27 2008-03-12 Daniel Drai Compositions and methods for enhancement of sexual function
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
AU2007287639A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
MX339136B (es) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
SG10201606751XA (en) 2011-05-13 2016-10-28 Eb Ip Hybritabs B V Drug Delivery System
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
SK89599A3 (en) * 1997-01-06 2000-12-11 Pfizer Rapidly releasing and taste-masking pharmaceutical dosage form
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
CA2342830C (en) * 1998-09-04 2008-11-25 Ortho-Mcneil Pharmaceutical, Inc. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction

Also Published As

Publication number Publication date
JP2002528408A (ja) 2002-09-03
PE20001286A1 (es) 2000-11-22
CZ20011427A3 (cs) 2001-10-17
EP1123088B1 (en) 2006-09-27
EA004068B1 (ru) 2003-12-25
AU756509B2 (en) 2003-01-16
EA200100298A1 (ru) 2001-08-27
MXPA01004011A (es) 2003-03-10
PL195789B1 (pl) 2007-10-31
DK1123088T3 (da) 2007-01-02
CA2348086C (en) 2007-01-23
HUP0104318A2 (hu) 2002-03-28
BG65323B1 (bg) 2008-02-29
UA67802C2 (uk) 2004-07-15
DE69933383T2 (de) 2007-02-01
PL347476A1 (en) 2002-04-08
MY130727A (en) 2007-07-31
HK1041818A1 (zh) 2002-07-26
NO20011933L (no) 2001-06-25
DE69933383D1 (de) 2006-11-09
NZ510275A (en) 2003-07-25
CN1324233A (zh) 2001-11-28
CY1106239T1 (el) 2011-06-08
TW577756B (en) 2004-03-01
CO5160262A1 (es) 2002-05-30
GT199900184A (es) 2001-04-14
ES2272082T3 (es) 2007-04-16
SK286473B6 (sk) 2008-11-06
AP2001002125A0 (en) 2001-04-04
SK5192001A3 (en) 2002-09-10
HUP0104318A3 (en) 2003-12-29
UY25765A1 (es) 2001-08-27
OA11664A (en) 2005-01-07
EP1123088A1 (en) 2001-08-16
NO20011933D0 (no) 2001-04-19
KR20010075659A (ko) 2001-08-09
BG105465A (bg) 2001-12-29
DZ2923A1 (fr) 2004-03-01
IS5865A (is) 2001-02-27
EE200100235A (et) 2002-08-15
MA26700A1 (fr) 2004-12-20
AU5878799A (en) 2000-05-15
BR9914718A (pt) 2001-07-10
CR6326A (es) 2004-02-23
ID28232A (id) 2001-05-10
IL141764A0 (en) 2002-03-10
PA8484301A1 (es) 2000-09-29
US6964780B1 (en) 2005-11-15
CA2348086A1 (en) 2000-05-04
PT1123088E (pt) 2007-01-31
IL141764A (en) 2008-06-05
HRP20010285A2 (en) 2002-06-30
ATE340562T1 (de) 2006-10-15
WO2000024383A1 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
SE9901272D0 (sv) New improved formulation
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
BR9711306A (pt) Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis
ATE231872T1 (de) Thiazolopyrimidinderivate
HRP20080612T3 (en) Combination of tenofovir, ritonavir and tmc114
TR199901104T2 (tr) Farmasötik bilesikler.
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
AU6469401A (en) Pharmaceutically active compounds and methods of use
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ES2194129T3 (es) Compuestos farmaceuticos.
AP2001002369A0 (en) Pharmaceutical complex.
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
CY2307B1 (en) Pharmaceutical composition for the administration of thiocolchicoside via the buccal mucosa.
ECSP993165A (es) Formulaciones farmaceuticas de liberacion controlada
AR019492A1 (es) COMPOSICIONES FARMACÉUTICAS DE LIBERACIoN CONTROLADA